CYDX
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
CYDX earns a Neutral rating with a 46 composite score and low conviction of 2/5. Fundamentals provide the principal support at 55, led by a perfect gross-margin subscore, a 70.1 revenue-growth subscore, and a 62.9 cash-runway subscore. Regulatory contributes 49, where an 80 enforcement subscore offsets a 25 cadence score and a neutral jurisdiction posture. Market performance scores 40 because institutional pricing feeds provide no available quote, while editorial scores 30 following no newsroom or brief activity in CIN newsroom coverage. The zero market-cap-tier subscore also limits the fundamental contribution and reinforces the middle-band outcome.
Licensed fundamentals data show year-over-year revenue growth of 20.1% and a gross margin near 60.9%, demonstrating commercial traction and strong unit economics. Those strengths fail to carry through the cost structure: the operating margin stands at negative 71.7%, EBITDA is negative by roughly $502,000, and the operating-margin subscore is only 21.8. Net income is modestly positive at approximately $136,500, but that result does not override the negative EBITDA profile or the stated stretched financial condition. The cash-burn ratio of about 0.065 and a market capitalization near $7.8 million further frame a small, financially constrained platform. Primary regulatory filings show no recorded events over either the latest 90-day or 180-day periods, no enforcement hits, and no available latest-filing timestamp, leaving cadence as the principal regulatory weakness.
The clearest catalyst rests within fundamentals, the highest-scoring pillar. Sustained revenue expansion combined with the existing gross-margin base can deliver substantial operating leverage if expense intensity declines, lifting the weak operating-margin and EBITDA components that currently cap the composite. Regulatory silence, absent institutional pricing, and limited CIN newsroom coverage offer no equivalent near-term driver, placing execution squarely on financial conversion rather than external sentiment. The single most important signal to watch is whether revenue growth and the roughly 61% gross margin translate into a materially less negative operating margin.
- IR / PR agency
- Preya Co.
- IR email
- Info@CYductDX.com
- IR page
- Investor relations
- Headquarters
- 1698 Post Rd. E Suite 1A Westport, CT 06880
- Phone
- +1-888-545-9112
- CEO
- Dominick Gatto
- CFO
- Claus Madsen
- SEC CIK
- 1388994
- Website
- Company website
- Market cap
- $7.8M
- Enterprise value
- $7.8M
- P/E ratio
- 1.9
- Price to sales
- 22.50
- Revenue (TTM)
- $345K
- Gross profit (TTM)
- $210K
- EBITDA
- $-502K
- Operating margin
- -71.7%
- Profit margin
- 39.6%
- Rev growth YoY
- 20.1%
- Return on equity
- 8.4%
- Return on assets
- -13.6%
- EPS (TTM)
- $0.77
- Shares outstanding
- 5.2M
- Beta
- -0.93
- Full-time employees
- 3
- GICS sector
- Healthcare
- GICS industry
- Medical Devices
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for CYDX (CYDX)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for CYDX (CYDX), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (2 bullish signals, 0 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CYDX are maintained by Cannabis Investor News and refreshed throughout the trading day.